7498 Results (Page 287 of 300)
Pharmaceuticals Markets Research Reports
South Africa Chronic Cough Therapeutics Market Analysis
South Africa Chronic Cough Therapeutics Market was valued at $41 Mn in 2022 and is estimated to reach $84 Mn in 2030, exhibiting a CAGR of 9.33% during the forecast period. The primary catalyst propelling the expansion of the chronic cough therapeutics market is the widespread prevalence of persistent coughing linked to chronic respiratory infections. Key players in this industry comprise Aspen Pharmacare, Pfizer, GlaxoSmithKline, Johnson & Johnson, Novartis, Sanofi, Merck & Co., AstraZeneca, Abbott Laboratories, and Chiesi Farmaceutici.
France Hypersomnia Therapeutics Market Analysis
The France Hypersomnia Therapeutics Market was valued at $11.50 Mn in 2023 and is predicted to grow at a CAGR of 4.73% from 2023 to 2030, to $15.89 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Jazz Pharmaceuticals, Pfizer, Takeda, and Novartis among others
Spain Chronic Cough Therapeutics Market Analysis
Spain Chronic Cough Therapeutics Market was valued at $122 Mn in 2022 and is estimated to reach $210 Mn in 2030, exhibiting a CAGR of 7.1% during the forecast period. The primary factor propelling the expansion of the chronic cough therapeutics market is the widespread occurrence of chronic respiratory infections, commonly indicated by the presence of persistent coughing. Currently, prominent players in this market include Boiron, AstraZeneca, GlaxoSmithKline, Sanofi, Pfizer, Merck, Johnson & Johnson, Novartis, Teva Pharmaceutical Industries, and Pierre Fabre Laboratories.
Germany Hypersomnia Therapeutics Market Analysis
The Germany Hypersomnia Therapeutics Market was valued at $5.06 Mn in 2023 and is predicted to grow at a CAGR of 5% from 2023 to 2030, to $7.12 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Janssen, Novartis, Pfizer, and Sanofi among others.
UAE Chronic Cough Therapeutics Market Analysis
UAE Chronic Cough Therapeutics Market was valued at $32 Mn in 2022 and is estimated to reach $63 Mn in 2030, exhibiting a CAGR of 9.1% during the forecast period. The main driver behind the growth of the chronic cough therapeutics market is the extensive prevalence of chronic respiratory infections, often signaled by the occurrence of chronic cough. Presently, key participants in this market consist of GlaxoSmithKline (GSK), Pfizer, McNeil Consumer Healthcare (Johnson & Johnson), Procter & Gamble (P&G), Reckitt Benckiser Group, Perrigo Company, Medtech Products Inc., Bionpharma Inc., A. Vogel Canada Inc., and Jamieson Laboratories.
Spain Hypersomnia Therapeutics Market Analysis
The Spain Hypersomnia Therapeutics Market was valued at $2.76 Mn in 2023 and is predicted to grow at a CAGR of 5.10% from 2023 to 2030, to $3.91 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Jazz Pharmaceuticals, Teva, Takeda, and Pfizer among others.
UK Chronic Cough Therapeutics Market Analysis
UK Chronic Cough Therapeutics Market was valued at $164 Mn in 2022 and is estimated to reach $263 Mn in 2030, exhibiting a CAGR of 6.1% during the forecast period. The key driver behind the growth of the chronic cough therapeutics market is the prevalent occurrence of chronic respiratory infections, often identified by persistent coughing. Leading participants in this market presently include GlaxoSmithKline, Pfizer, Reckitt Benckiser, Boots, Sanofi, AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, and Teva Pharmaceutical Industries.
UK Hypersomnia Therapeutics Market Analysis
The UK Hypersomnia Therapeutics Market was valued at $3.70 Mn in 2023 and is predicted to grow at a CAGR of 4.70% from 2023 to 2030, to $5.10 Mn by 2030. The key drivers of this industry include increasing awareness, lifestyle changes, expanding geriatric population, and early detection. The key players in the industry are GSK, Hoffmann-La Roche Ltd, Sanofi, and Novartis among others.
US Chronic Cough Therapeutics Market Analysis
US Chronic Cough Therapeutics Market was valued at $2646 Mn in 2022 and is estimated to reach $4249 Mn in 2030, exhibiting a CAGR of 6.1% during the forecast period. The key driver behind the growth of the chronic cough therapeutics market is the high prevalence of chronic respiratory infections, as chronic cough commonly signals the presence of such conditions. Presently, leading contributors to this market comprise GlaxoSmithKline (GSK), Pfizer, McNeil Consumer Healthcare (Johnson & Johnson), Procter & Gamble (P&G), Reckitt Benckiser Group, Perrigo Company, Medtech Products Inc., Bionpharma Inc., A. Vogel Canada Inc. and Jamieson Laboratories.
China Hypersomnia Therapeutics Market Analysis
The China Hypersomnia Therapeutics Market was valued at $59.80 Mn in 2023 and is predicted to grow at a CAGR of 2.50% from 2023 to 2030, to $71.08 Mn by 2030. The key drivers of this industry include increasing awareness, lifestyle changes, expanding geriatric population, and early detection. The key players in the industry are Teva, Takeda, Jiangsu Hengrui Medicine Co., Ltd., Shanghai Junshi Biosciences Co., Ltd., and Jazz Pharmaceuticals among others.
Indonesia Hypersomnia Therapeutics Market Analysis
The Indonesia Hypersomnia Therapeutics Market was valued at $84.18 Mn in 2023 and is predicted to grow at a CAGR of 2.70% from 2023 to 2030, to $101.44 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Kalbe Farma, Dexca Medica, Teva, Takeda, and Indofarma among others.
Brazil Conjunctivitis Therapeutics Market Analysis
The Brazil Conjunctivitis Therapeutics Market was valued at $103 Mn in 2022 and is predicted to grow at a CAGR of 6.4% from 2023 to 2030, to $168 Mn by 2030. The key drivers of this industry include the rising prevalence of conjunctivitis, expanding healthcare accessibility, and expanding pharmaceutical landscape in the industry. The industry is primarily dominated by players such as Novartis, Pfizer, Bausch & Lomb, Sanofi, Santen, and Allergan among others.
Japan Hypersomnia Therapeutics Market Analysis
The Japan Hypersomnia Therapeutics Market was valued at $63.25 Mn in 2023 and is predicted to grow at a CAGR of 3.5% from 2023 to 2030, to $80.47 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Aculys Pharma Inc., Teva, Takeda, and Eisai among others.
Malaysia Hypersomnia Therapeutics Market Analysis
The Malaysia Hypersomnia Therapeutics Market was valued at $44.39 Mn in 2023 and is predicted to grow at a CAGR of 3.50% from 2023 to 2030, to $56.48 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Jazz Pharmaceuticals, Pfizer, Teva Pharmaceuticals, and GSK among others.
Singapore Hypersomnia Therapeutics Market Analysis
The Singapore Hypersomnia Therapeutics Market was valued at $39.10 Mn in 2023 and is predicted to grow at a CAGR of 6% from 2023 to 2030, to $58.79 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Pfizer, Sanofi, Sphaera Pharma, and Raffles Medical among others.
Egypt Conjunctivitis Therapeutics Market Analysis
The Egypt Conjunctivitis Therapeutics Market was valued at $11 Mn in 2022 and is predicted to grow at a CAGR of 6.9% from 2023 to 2030, to $20 Mn by 2030. The key drivers of this industry include the rising prevalence of conjunctivitis, expanding healthcare infrastructure, and the evolving treatment landscape. The industry is primarily dominated by players such as Allergan, Sun Pharma, Novartis, Sirion, Boehringer Ingelheim, Pfizer, and Auven among others.
Philippines Hypersomnia Therapeutics Market Analysis
The Philippines Hypersomnia Therapeutics Market was valued at $11.50 Mn in 2023 and is predicted to grow at a CAGR of 5.50% from 2023 to 2030, to $16.73 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Novartis, Pfizer, Johnson & Johnson, and GSK among others.
Vietnam Hypersomnia Therapeutics Market Analysis
The Vietnam Hypersomnia Therapeutics Market was valued at $6.44 Mn in 2023 and is predicted to grow at a CAGR of 6% from 2023 to 2030, to $9.68 Mn by 2030. The key drivers of this industry include increasing awareness, lifestyle changes, expanding geriatric population, and early detection. The key players in the industry are Teva, Jazz Pharmaceuticals, ImexPharma, Sanofi, and Pfizer among others.
Germany Conjunctivitis Therapeutics Market Analysis
The Germany Conjunctivitis Therapeutics Market was valued at $150 Mn in 2022 and is predicted to grow at a CAGR of 3.6% from 2023 to 2030, to $199 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of conjunctivitis, favorable reimbursement conditions, and the development of new drugs in the industry. The industry is primarily dominated by players such as Allergan, Pfizer, Bausch & Lomb, Auven, and Santen among others.
Egypt Hypersomnia Therapeutics Market Analysis
The Egypt Hypersomnia Therapeutics Market was valued at $14.95 Mn in 2023 and is predicted to grow at a CAGR of 5.73% from 2023 to 2030, to $22.08 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Delta Pharma, Teva, Sedico Pharmaceuticals, and Takeda Pharmaceuticals among others.
Indonesia Conjunctivitis Therapeutics Market Analysis
The Indonesia Conjunctivitis Therapeutics Market was valued at $25 Mn in 2022 and is predicted to grow at a CAGR of 5.4% from 2023 to 2030, to $37 Mn by 2030. The primary factors propelling this industry forward include the increasing prevalence of conjunctivitis, technological advancements, increasing government focus on preventative care, and others. The industry is primarily dominated by players such as Allergan, Bausch & Lomb, Alcon, Roche, Novartis, Santen, and Johnson & Johnson among others.
Kenya Hypersomnia Therapeutics Market Analysis
The Kenya Hypersomnia Therapeutics Market was valued at $1.61 Mn in 2023 and is predicted to grow at a CAGR of 5.60% from 2023 to 2030, to $2.36 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Merck & Co., Sanofi SA, Johnson & Johnson, and GSK among others.
Japan Conjunctivitis Therapeutics Market Analysis
The Japan Conjunctivitis Therapeutics Market was valued at $255 Mn in 2022 and is predicted to grow at a CAGR of 5.9% from 2023 to 2030, to $403 Mn by 2030. The key drivers of this industry include the rising prevalence of conjunctivitis, technological advancements in the industry, and growing consumer demand for effective treatments. The industry is primarily dominated by players such as Allergan, Bausch & Lomb, Roche, Novartis, Santen, and Johnson & Johnson among others.
South Africa Hypersomnia Therapeutics Market Analysis
The South Africa Hypersomnia Therapeutics Market was valued at $57.50 Mn in 2023 and is predicted to grow at a CAGR of 5.50% from 2023 to 2030, to $83.64 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Cipla Medpro, Novartis, Pfizer, and Sanofi among others.
Kenya Conjunctivitis Therapeutics Market Analysis
The Kenya Conjunctivitis Therapeutics Market was valued at $3 Mn in 2022 and is predicted to grow at a CAGR of 6.5% from 2023 to 2030, to $5 Mn by 2030. The key drivers of this industry include the rising prevalence of conjunctivitis, the growing pharmaceutical industry, and supportive government initiatives. The industry is primarily dominated by players such as Allergan, Novartis, Sirion, Boehringer Ingelheim, Pfizer, and others.
